Want to see XERS full AI Analyst Report?
XERS Stock Chart & Stats
$8.32
$0.03(0.36%)
At close: 4:00 PM EDT
$8.32
$0.03(0.36%)
Day’s Range― - ―
52-Week Range$5.25 - $10.08
Previous CloseN/A
Volume106.69K
Average Volume (3M)2.07M
Market Cap
$1.55B
Enterprise Value$1.54K
Total Cash (Recent Filing)$121.75M
Total Debt (Recent Filing)$289.44M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Nov 05, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding182,320,310
10 Day Avg. Volume1,551,078
30 Day Avg. Volume2,072,983
Financial Highlights & Ratios
PEG Ratio-22.22
Price to Book (P/B)92.00
Price to Sales (P/S)4.32
P/FCF Ratio45.09
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$12.00Price Target Upside44.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$387.25M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained very high gross margins (~83–86%) reflect advantaged formulations and favorable product mix, providing durable product-level economics. High gross margins create cushion to fund commercial expansion and R&D while supporting long-term cash generation even as SG&A rises.
Strong Operating Cash GenerationMaterial positive operating and free cash flow demonstrates the business converting revenue into cash after expenses. This improves financing optionality, funds growth investments and debt paydowns, and materially reduces reliance on external capital across the next several quarters.
Commercial Momentum And Durable PortfolioRapid Recorlev adoption plus Keveyis patent protection signal both near-term revenue runway and longer-term product durability. Strong Recorlev growth drives revenue diversification, while Keveyis IP secures a steady, rare-disease cash flow tail that supports commercial investment plans.
Bears Say
Elevated Leverage And Negative EquitySizable debt and a negative equity balance materially weaken financial flexibility and increase refinancing risk. A fragile equity cushion makes the company more sensitive to setbacks or larger spend programs, potentially raising cost of capital and constraining strategic optionality.
Inconsistent Profitability (TTM Net Loss)Although product economics and operating profit improved, the trailing net loss highlights earnings volatility driven by nonrecurring items and prior large losses. Persistent inconsistency can hinder self-funding for clinical programs and complicate planning for multi-year commercialization investments.
Higher Near-term Operating Spend And Program Timing RiskPlanned increases in SG&A and R&D to scale Recorlev and advance XP-8121 will pressure free cash flow and require disciplined execution. Coupled with Phase III enrollment/timing uncertainty, higher spend raises execution risk and could necessitate additional financing if outcomes or timelines slip.
Xeris Pharmaceuticals News
XERS FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest stock price was $5.25 and its highest was $10.08 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $1.55B.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 83 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of $0.012 by -$0.192.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is 0.04.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 182,320,310 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of -$0.18 in its last earnings report, missing expectations of $0.012. Following the earnings report the stock price went down -9.248%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in XERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xeris Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (44.23% Upside)
$12.00 (44.23% Upside)
Blogger Sentiment
Bullish
XERS Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.07%
Trailing 12-Months
Company Description
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
XERS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum (notably Recorlev’s 81% YoY growth), improved profitability (86% gross margin, adjusted EBITDA +50% YoY), strategic wins (Keveyis patent protection, retirement of convertible notes) and material pipeline progress for XP-8121 (multiple patents, Phase III planned by year-end). Lowlights were largely manageable: a one-time non-cash GAAP charge of ~$31M, higher near-term SG&A and R&D investments to fund growth and XP-8121, earlier-year softness in Gvoke that has since rebounded, and some remaining timing/enrollment uncertainty around Phase III. Overall, positive commercial execution and balance sheet actions outweigh the near-term charges and increased investment cadence.View all XERS earnings summariesXERS Stock 12 Month Forecast
Average Price Target
$12.00
▲(44.23% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Zymeworks
―
Arcus Biosciences
―
Stoke Therapeutics
―
Rapport Therapeutics, Inc.
―
Ownership Overview
5.10% Insiders
10.49% Mutual Funds
3.48% Other Institutional Investors
67.20% Public Companies and
Individual Investors